News

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

  • SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that between July 8-14, 2025, two new employees were granted inducement awards consisting of stock options to purchase an aggregate of 10,372 shares of common stock.
    07/18/2025

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

  • SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place June 24 to 28 in Phoenix, Arizona.
    06/24/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Aardvark Therapeutics, Inc. Common Stock (AARD) can sell. Click on Rating Page for detail.

The price of Aardvark Therapeutics, Inc. Common Stock (AARD) is 12.61 and it was updated on 2025-08-06 13:00:27.

Currently Aardvark Therapeutics, Inc. Common Stock (AARD) is in undervalued.

News
    
News

Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet

  • The mean of analysts' price targets for Aardvark Therapeutics, Inc. (AARD) points to an 180.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
    Tue, Jun. 03, 2025

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

  • SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointments of key members of its leadership team, including Timothy Kieffer, Ph.D., as Chief Scientific Officer; Danny Villeneuve as Chief Commercial Officer; Terrie Kellmeyer, Ph.D., as Senior Vice President, Regulatory Affairs; and Christian Zapf, J.D., as General Counsel.
    Mon, May. 19, 2025

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

  • Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. “We believe that there is a significant, untapped opportunity to target anti-hunger signaling to treat rare metabolic diseases and obesity.
    Wed, May. 14, 2025

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

  • SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during May:
    Wed, May. 07, 2025

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

  • SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December 31, 2024, and provided business highlights.
    Mon, Mar. 31, 2025
SEC Filings
SEC Filings

Aardvark Therapeutics, Inc. Common Stock (AARD) - 4

  • SEC Filings
  • 06/13/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - SCHEDULE 13G

  • SEC Filings
  • 05/15/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - 8-K - Current report

  • SEC Filings
  • 05/14/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/14/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - 8-K - Current report

  • SEC Filings
  • 03/31/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - 10-K - Current report

  • SEC Filings
  • 03/31/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - SCHEDULE 13G

  • SEC Filings
  • 02/24/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - 4

  • SEC Filings
  • 02/19/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - 8-K - Current report

  • SEC Filings
  • 02/14/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - EFFECT

  • SEC Filings
  • 02/13/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - S-8

  • SEC Filings
  • 02/13/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - 424B4

  • SEC Filings
  • 02/13/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - CERT

  • SEC Filings
  • 02/12/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - 3

  • SEC Filings
  • 02/12/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - CORRESP

  • SEC Filings
  • 02/10/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - 8-A12B

  • SEC Filings
  • 02/10/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - S-1/A

  • SEC Filings
  • 02/06/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - CORRESP

  • SEC Filings
  • 01/31/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - S-1

  • SEC Filings
  • 01/23/2025

Aardvark Therapeutics, Inc. Common Stock (AARD) - DRS/A

  • SEC Filings
  • 12/23/2024

Aardvark Therapeutics, Inc. Common Stock (AARD) - DRSLTR

  • SEC Filings
  • 12/20/2024

Aardvark Therapeutics, Inc. Common Stock (AARD) - UPLOAD

  • SEC Filings
  • 12/10/2024

Aardvark Therapeutics, Inc. Common Stock (AARD) - DRSLTR

  • SEC Filings
  • 11/27/2024

Aardvark Therapeutics, Inc. Common Stock (AARD) - DRS/A

  • SEC Filings
  • 11/27/2024

Aardvark Therapeutics, Inc. Common Stock (AARD) - UPLOAD

  • SEC Filings
  • 11/21/2024

Aardvark Therapeutics, Inc. Common Stock (AARD) - DRS

  • SEC Filings
  • 10/24/2024

Aardvark Therapeutics, Inc. Common Stock (AARD) - D

  • SEC Filings
  • 05/15/2024

Aardvark Therapeutics, Inc. Common Stock (AARD) - D

  • SEC Filings
  • 06/07/2021

Aardvark Therapeutics, Inc. Common Stock (AARD) - D

  • SEC Filings
  • 05/24/2019
More Headlines
News

Biotechs Highlight 6 Stocks Insiders Are Buying Now

  • Biotech companies saw the most notable insider purchases of the past week, including at the latest of the recent handful of biotech initial public offerings.
  • 02/23/2025

U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week

  • Seven IPOs and three SPACs were listed this week. Seven IPOs and four SPACs submitted initial filings. Some small IPOs are tentatively scheduled for the short holiday week ahead.
  • 02/14/2025

Aardvark Therapeutics Announces Pricing of Initial Public Offering

  • SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the pricing of its initial public offering of 5,888,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Aardvark. The gross proceeds to Aardvark from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $94.2 million. Aardvark's common stock is expected to begin trading on the Nasdaq Global Select Market on February 13, 2025 under the ticker symbol “AARD.” The offering is expected to close on February 14, 2025, subject to the satisfaction of customary closing conditions. In addition, Aardvark has granted the underwriters a 30-day option to purchase up to an additional 883,200 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • 02/12/2025

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

  • Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial Group, and Huachen AI Parking Management Technology. Eight IPOs are currently scheduled to list in the week ahead, although some small issuers may also join the calendar throughout the week.
  • 02/08/2025

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

  • Aardvark Therapeutics aims to raise $100 million in an IPO to fund its clinical-stage biopharma treatments for metabolic conditions, including Prader-Willi syndrome. Its lead candidate ARD-101, targeting hyperphagia, is entering Phase 3 trials with topline data expected in early 2026. The PWS market is projected to exceed $1 billion by 2034, presenting significant growth potential despite its rarity.
  • 02/03/2025
Unlock
AARD Ratings Summary
AARD Quant Ranking